Johnson & Johnson: Pharma Growth Strategy

Summary

For competitors and investors alike this is a key question, and one that must be considered in the light of two recent and significant developments.

• The acquisition by Johnson & Johnson of Cougar Biotechnology for almost US$1 billion in May 2009 spearheads a move by the company to become a top 5 player in the fast-growing oncology sector - a therapy area relatively new to J&J.
• An audacious move to secure the non-US distribution rights to Remicade and Simponi from Schering-Plough; a move triggered by the proposed merger of Schering-Plough with Merck & Co. If successful, this would add significant revenues to J&J's coffers at a stroke.

The focus on novel oncology product development is timely. Although J&J can boast 9 blockbusters in its product line-up, it is feeling the pressure of generic competition on Risperdal and Topamax; a situation that will not be improved by the loss of patent protection for Levaquin and Remicade in the medium term.

Easily assess J&J's strategy!

For a complete and concise assessment of J&J's strategic thinking and development, turn to this new Firstword report Johnson & Johnson: Pharma Growth Strategy. Using primary source data and information, this 25-page report presents a timely, comprehensive yet easy-to-read briefing for all executives tracking developments at one of the industry's major players.

This sharply-focussed, cost-effective report will tell you:

• the current product range and sales performance;
• J&J's strategic plan and how is it being deployed;
• the focus of J&J's research pipeline and the ambition for oncology market leadership;
• the strategic thinking underpinning development in key emerging markets, such as India and China;
• the implications of the Merck & Co/Schering-Plough merger for J&J; and
• expected product filings in key markets around the world.

Contents

• Executive Summary
• Current Situation - A Summary
  • J&J - Key Pharmaceutical Revenues, 2007-2009
• Strategy
  • Key Elements of the Strategy
  • An Evolving Portfolio
  • NME Approvals/Filings, 2007-2013
  • NME Approvals/Filings, 2008 - date
  • Major Line Extensions, 2008 - date
  • Robust Pipeline
  • Planned NME Filings, 2009 - 2013
  • Potential Line Extensions by 2013
  • Potential in Emerging Markets
  • Potential Filings in India, China and Japan, 2009-2013
  • Pipeline in a Product
• Pharma R&D Strategy
  • Focus on Oncology
  • Oncology Highlights
  • Velcade
  • Doxil
  • Yondelis
  • Tumour Microenvironment Disrupting Agents
  • Biomarkers and Diagnostics
  • Tianjin Medical
  • University Cancer Institute and Hospital
  • Cougar Biotechnology
  • Cougar Biotechnology Acquisition
  • Cougar Portfolio
  • Recent Clinical Trial Results
• Merck/Schering-Plough Merger
  • Significance to Johnson & Johnson
  • Remicade
  • Simponi
  • Issues over Simponi
  • Acquisition of Elan's Alzheimer's immunotherapy (AI) programme
  • Reference Table - Late-Stage R&D Pipeline, April 2009
• Index
• Recent Articles